Effect of Cognitive Behavioral Therapy for Insomnia on Alcohol Treatment Outcomes Among US Veterans
Importance
Three of 4 adults in treatment for alcohol use disorder (AUD) report symptoms of insomnia. Yet the first-line treatment for insomnia (cognitive behavioral therapy for insomnia, CBT-I) is often delayed until abstinence is established.
Objective
To test the feasibility, acceptability, and preliminary efficacy of CBT-I among veterans early in their AUD treatment and to examine improvement in insomnia as a mechanism for improvement in alcohol use outcomes.
Design, Setting, and Participants
For this randomized clinical trial, participants were recruited through the Addictions Treatment Program at a Veterans Health Administration hospital between 2019 and 2022. Patients in treatment for AUD were eligible if they met criteria for insomnia disorder and reported alcohol use in the past 2 months at baseline. Follow-up visits occurred posttreatment and at 6 weeks.
Interventions
Participants were randomly assigned to receive 5 weekly sessions of CBT-I or a single session about sleep hygiene (control). Participants were asked to complete sleep diaries for 7 days at each assessment.
Main Outcomes and Measures
Primary outcomes included posttreatment insomnia severity (assessed using the Insomnia Severity Index) and follow-up frequency of any drinking and heavy drinking (4 drinks for women, ≥5 drinks for men; number of days via Timeline Followback) and alcohol-related problems (Short Inventory of Problems). Posttreatment insomnia severity was tested as a mediator of CBT-I effects on alcohol use outcomes at the 6-week follow-up.
Results
The study cohort included 67 veterans with a mean (SD) age of 46.3 years (11.8); 61 (91%) were male and 6 (9%) female. The CBT-I group included 32 participants, and the sleep hygiene control group 35 participants. Of those randomized, 59 (88%) provided posttreatment or follow-up data (31 CBT-I, 28 sleep hygiene). Relative to sleep hygiene, CBT-I participants reported greater decreases in insomnia severity at posttreatment (group × time interaction: −3.70; 95% CI, −6.79 to −0.61) and follow-up (−3.34; 95% CI, −6.46 to −0.23) and greater improvements in sleep efficiency (posttreatment, 8.31; 95% CI, 1.35 to 15.26; follow-up, 18.03; 95% CI, 10.46 to 25.60). They also reported greater decreases in alcohol problems at follow-up (group × time interaction: −0.84; 95% CI, −1.66 to −0.02), and this effect was mediated by posttreatment change in insomnia severity. No group differences emerged for abstinence or heavy-drinking frequency.
Conclusions and Relevance
In this randomized clinical trial, CBT-I outperformed sleep hygiene in reducing insomnia symptoms and alcohol-related problems over time but had no effect on frequency of heavy drinking. CBT-I should be considered a first-line treatment for insomnia, regardless of abstinence.
Trial Registration
ClinicalTrials.gov Identifier:
Top-30
Journals
|
1
2
3
|
|
|
Sleep Medicine Reviews
3 publications, 12.5%
|
|
|
Sleep
2 publications, 8.33%
|
|
|
Alcohol Clinical and Experimental Research
2 publications, 8.33%
|
|
|
Behavioral Sleep Medicine
2 publications, 8.33%
|
|
|
Psychiatric Annals
1 publication, 4.17%
|
|
|
Current Addiction Reports
1 publication, 4.17%
|
|
|
Alcohol and Alcoholism
1 publication, 4.17%
|
|
|
Sleep and Biological Rhythms
1 publication, 4.17%
|
|
|
JAMA Psychiatry
1 publication, 4.17%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 4.17%
|
|
|
Alcohol
1 publication, 4.17%
|
|
|
Current Sleep Medicine Reports
1 publication, 4.17%
|
|
|
Substance Use and Misuse
1 publication, 4.17%
|
|
|
Journal of Psychiatric Practice
1 publication, 4.17%
|
|
|
Current Psychiatry Reports
1 publication, 4.17%
|
|
|
Pharmaceuticals
1 publication, 4.17%
|
|
|
Journal of Psychiatric Research
1 publication, 4.17%
|
|
|
SLEEP Advances
1 publication, 4.17%
|
|
|
Sleep Medicine
1 publication, 4.17%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
|
|
|
Elsevier
6 publications, 25%
|
|
|
Oxford University Press
4 publications, 16.67%
|
|
|
Springer Nature
4 publications, 16.67%
|
|
|
Taylor & Francis
3 publications, 12.5%
|
|
|
Wiley
2 publications, 8.33%
|
|
|
SLACK
1 publication, 4.17%
|
|
|
American Medical Association (AMA)
1 publication, 4.17%
|
|
|
Frontiers Media S.A.
1 publication, 4.17%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 4.17%
|
|
|
MDPI
1 publication, 4.17%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.